| (690) Lung Transplant for Severe Covid-19-Related Acute Lung Injury: Promise or Over-Enthusiasm? Clinical Characteristics and Outcomes of Patients Bridged on Extracorporeal … O Deri, L Levy, E Huszti, E Nachum, S Ladot, N Shimoni, M Saute, ... The Journal of Heart and Lung Transplantation 42 (4), S305-S306, 2023 | | 2023 |
| 1217P B cell infiltration and memory TOX+ CD8+ T cells in stage I-II non-small cell lung cancer (NSCLC) predict response to neoadjuvant pembrolizumab: A phase I study J Bar, N Maimon, Y Glantzspiegel, I Kamer, O Zadok, E Ofek, ... Annals of Oncology 35, S783-S784, 2024 | | 2024 |
| 1285P Deep learning prediction of response to advanced-generation ALK inhibitors (aALKi) in ALK-rearranged advanced NSCLC (aNSCLC) patients using digital pathology A Stemmer, K Parikh, YC Lo, P Shakya, W Klaisuban, I Vardi, D Urban, ... Annals of Oncology 35, S819, 2024 | | 2024 |
| 1311P Phase II, open-label study of frontline tusamitamab ravtansine with pembrolizumab±chemotherapy in advanced non-squamous non-small cell lung cancer: Updated results from … DR Abreu, R Veillon, M Ravoire, JL Gonzalez-Larriba, FJ Orlandi, T Nagy, ... Annals of Oncology 35, S834, 2024 | | 2024 |
| 1359P Clinical characteristics of advanced NSCLC patients with phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutations SN Daher, R Yacobi, I Barshack, S Tsabari, Y Rotenberg, T Kuznetsov, ... Annals of Oncology 31, S870, 2020 | | 2020 |
| 13MO Safety and efficacy of tusamitamab ravtansine in combination with pembrolizumab±chemotherapy in patients with CEACAM5-positive nonsquamous NSCLC (CARMEN-LC05 phase II study) N Isambert, T Nagy, M Ravoire, D Rodriguez-Abreu, JL Gonzalez-Larriba, ... Journal of Thoracic Oncology 18 (4), S46-S47, 2023 | 3 | 2023 |
| 150P Correlation between erlotinib-induced rash and efficacy in first-line therapy of patients with advanced non-small cell lung cancer (NSCLC) expressing epidermal growth … M Gottfried, SK Rosenberg, J Dudnik, M Wollner, J Bar, A Onn, O Frenkel, ... Journal of Thoracic Oncology 13 (4), S90-S91, 2018 | 2 | 2018 |
| 239 Smoking History as a Predictive Factor of Treatment Response in Advanced Non–Small-Cell Lung Cancer: A Systematic Review Paul Mitchell, Tony Mok, Helen Barraclough, Alena … T Reungwetwattana, SJ Weroha, JR Molina, J Bar, A Onn, W Jiang, ... | | |
| 3rd-line anaplastic lymphoma kinase (ALK) inhibitors (ALKi) in advanced non-small cell lung cancer (aNSCLC): Real-world comparison to non-ALKi therapy. N Maimon, E Dudnik, Y Rottenberg, N Popovits-Hadari, N Asna, ... Journal of Clinical Oncology 38 (15_suppl), e21685-e21685, 2020 | | 2020 |
| 523 Initial clinical experience with pembrolizumab in metastatic heavily pre-treated patients with solid cancers in a single institution R Leibowitz-Amit, R Shapira-Frommer, T Golan, J Korach, A Israel, ... European Journal of Cancer 3 (51), S111, 2015 | 1 | 2015 |
| A better crystal ball to predict lung-cancer survival? A Onn, BF Dickey The Lancet Oncology 7 (10), 789-790, 2006 | 6 | 2006 |
| A combination of approved antibodies overcomes resistance of lung cancer to osimertinib by blocking bypass pathways D Romaniello, L Mazzeo, M Mancini, I Marrocco, A Noronha, M Kreitman, ... Clinical Cancer Research 24 (22), 5610-5621, 2018 | 47 | 2018 |
| A comparative analysis of total serum miRNA profiles identifies novel signature that is highly indicative of metastatic melanoma: a pilot study E Greenberg, MJ Besser, E Ben-Ami, R Shapira-Frommer, O Itzhaki, ... Biomarkers 18 (6), 502-508, 2013 | 50 | 2013 |
| A non-invasive method for early detection of aneuploid cells in potentially malignant oral lesions A Hirshberg, T Shani, A Onn, A Kabha, M Vered, I Ben-Dov, Y Yahalom, ... ORAL DISEASES 16 (6), 535-535, 2010 | | 2010 |
| A novel artificial intelligence based denoising method for ultra-low dose CT used for lung cancer screening L Gorenstein, A Onn, M Green, A Mayer, S Segev, EM Marom Academic Radiology 30 (11), 2588-2597, 2023 | 4 | 2023 |
| A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer V Lazar, E Rubin, S Depil, Y Pawitan, JF Martini, J Gomez-Navarro, ... Oncotarget 6 (16), 14139, 2015 | 30 | 2015 |
| A single-arm phase II study of afatinib treatment for advanced EGFR-mutant non-small cell lung cancer (mNSCLC) patients (pts) with EGFR-tyrosine kinase inhibitor (TKI) resistance. J Bar, D Botser, R Navon, N Peled, H Biran, EN Gal-Yam, S Ben-Arieh, ... Journal of Clinical Oncology 33 (15_suppl), e19031-e19031, 2015 | 3 | 2015 |
| A transcriptomics approach to expand therapeutic options and optimize clinical trials in oncology V Lazar, B Zhang, S Magidi, C Le Tourneau, E Raymond, M Ducreux, ... Therapeutic Advances in Medical Oncology 15, 17588359231156382, 2023 | 4 | 2023 |
| A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non‐small cell lung cancer B Solomon, A Callejo, J Bar, G Berchem, L Bazhenova, P Saintigny, ... Cancer medicine 11 (14), 2790-2800, 2022 | 11 | 2022 |
| A5-02: Targeted therapy against VEGFR and/or EGFR signaling with AZD2171, vandetanib, and gefitinib as part of a combined modality approach for the treatment of non-small-cell … MS O'Reilly, K Furutani, W Wu, A Onn, A Ryan, JM Jürgensmeier, ... Journal of Thoracic Oncology 2 (8), S323, 2007 | | 2007 |
